DOCSLIB.ORG

Improving Insight Into Radiobiology and Radionuclide Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Improving Insight Into Radiobiology and Radionuclide Therapy Improving Insight into Radiobiology and Radionuclide Therapy large quantities of similar nonlabeled type of emission, and energy of emis- In 1969, Edith Quimby, ScD, one of compounds. sion) of a radionuclide and the radio- the founders of modern radionuclide do- In kidneys removed from 3 patients biologic response elicited. This issue simetry, concluded her presentation at an with primary renal tumors, de Jong et al. goes beyond the specific application of Atomic Energy Commission symposium (2) have demonstrated by autoradiogra- radiolabeled peptides in the treatment at the Oak Ridge Associated Universities phy a nonuniform distribution pattern for of neuroendocrine tumors. Currently, entitled “Medical Radionuclides: Radia- the radiolabeled peptide. The radiolabel the nuclear medicine community has tion Dose and Effects” with the state- is deposited in linear bands, most prom- available 2 radiolabeled antibodies ap- ment: “Radionuclide dosimetry is not a inently in the inner renal cortex and also proved by the U.S. Food and Drug in the renal medulla. Unfortunately, de Administration for the treatment of finished product, but it has come a long Jong’s group has not yet analyzed the non-Hodgkin’s lymphoma, one labeled way from the early empiric days. We precise histologic distribution on com- with 90Y and the other with 131I. At this must be grateful to the patient people panion sections stained with hematoxy- time, there has not been a randomized who have spent untold hours on these lin and eosin, but the autoradiographs comparison of the 2 agents. Given the developments.” (1). demonstrate the highest deposition of ra- numerous variables in patient selec- Thirty-five years later, this statement dionuclide in a well-defined pattern that tion, one wonders if a clinical trial will is still relevant. It has been confirmed by is sure to correlate with specific struc- resolve the question of therapeutic su- the efforts of Marion de Jong et al. from tures. Although drawing conclusions periority. My own group has been The Netherlands, as reported on pages would be premature, I find the pattern evaluating the relative merits of 90Y- 1168–1171 of this issue of The Journal quite suggestive of deposition in the and 177Lu-labeled monoclonal antibod- of Nuclear Medicine (2). de Jong et al. proximal and perhaps distal convoluted ies in the therapy of metastatic pros- have convincingly demonstrated that, in tubules. The proximal convoluted tubule tatic cancer (7). radionuclide dosimetry, it is not valid to is the site of reabsorption of amino acids The observations and subsequent dis- assume a uniform distribution of radia- from the glomerular filtrate and, so, is cussion of de Jong et al. (2) reinforce the tion sources in a target organ and, hence, likely also the site of reabsorption of a notion that one must consider microdo- that it is not appropriate to compare ra- small peptidelike octreotide and other simetry in order to understand the radio- diation effects from absorbed doses de- somatostatin analogs. biology of antitumor effects and organ or livered by external-beam sources with Accurate demonstration of the pre- tissue toxicity. The early Quimby–Ma- doses from injected radionuclides. cise localization of the site of reabsorp- rinelli formulation and the subsequent The radiation-absorbed dose to the tion may assist in identifying drugs or MIRD formulation enable us to deter- kidneys is a particular problem in the other compounds that would be more mine the radiation-absorbed dose to or- clinical assessment of peptide-based effective in blocking or inhibiting the gans and tissues independent of the ra- targeted radionuclide therapy of islet tubular reabsorption and subsequent dionuclide. These formulations account cell adenocarcinoma, malignant carci- deposition of the radiolabel. for differences in the administered dose, noid tumors, and other somatostatin- Even while de Jong et al. (2) and the physical and biologic half-life of the others (3–5) have been trying to better different radionuclides, and the specific receptor–positive tumors. The fraction relate the renal radiation-absorbed type and energy of the emission after of an injected dose of radiolabeled dose, as it is currently measured, to each nuclear disintegration. The MIRD peptide retained in the kidneys can be nephrotoxicity from 90Y-labeled pep- formulation also incorporates Monte reduced by amino acid infusions when tide therapy and to take measures to Carlo statistics to further rationalize the a labeled peptide or antibody fragment reduce that dose, the Rotterdam group randomness of the radiation emission has been administered. This practice is has been trying also to determine the and the distance and direction between a now standard in clinical protocols relative therapeutic merits and poten- source and target organ or tissue. Never- evaluating radiolabeled somatostatin tial toxicity of 90Y and 177Lu as labels theless, compared with the absorbed analogs as therapeutic agents. The for therapeutic uses (6). dose for uniform external-beam radia- logic behind this approach is to inhibit It is desirable from a scientific, di- tion therapy, the overall radiation-ab- reabsorption of the radiolabeled pep- dactic, and clinical perspective to un- sorbed dose calculated for radionuclide tide that appears in the glomerular fil- derstand the relationship between the therapy often does not correlate with the trate by administering comparatively physical properties (physical half-life, therapeutic or toxic effects observed. 1104 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 45 • No. 7 • July 2004 Questions remain about the differences gan or tissue refocuses the spotlight on from the early empiric days. We must in therapeutic and toxic effects from dif- differences between radionuclides in be grateful to the patient people who ferent radionuclides despite administra- terms of pathlength and linear energy have spent untold hours on these de- tion of similar radiation-absorbed doses. deposition, both functions of the en- velopments.” (1). Are these differences due to dose ergy of the specific emission. Until rate effects? This possibility was en- now, in Quimby–Marinelli and MIRD thusiastically considered a few years formulations, in contrast to ␥-radiation Stanley J. Goldsmith, MD ago, when the radionuclide therapy of and x-rays (penetrating radiation), we New York Weill Cornell Medical Center painful bone metastases was attracting have assigned a uniform absorbed- New York, New York attention. Because clinical trials vary fraction value to all nonpenetrating ra- so much in patient demographics, it diation (␣, ␤, and Auger). If the source REFERENCES was desirable to identify a scientific and target were the same, it was as- 1. Quimby E. The development of radiation dosimetry basis for selection among the several sumed that 100% of the energy from in nuclear medicine. In: Medical Radionuclides: Ra- diation Dose and Effects. Washington, DC: U.S. 89 153 166 radionuclides ( Sr, Sm, Re, and nonpenetrating emissions was ab- Atomic Energy Commission; 1970:7–15. AEC Sym- 87mSn) available for clinical trials. To sorbed (absorbed fraction ϭ 1.0); if the posium Series 20. date, no convincing evidence exists target was distant from the source, ab- 2. de Jong M, Valkema R, van Gameren A, et al. that differences in the physical half- sorbed fraction was assigned a value of Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]oct- lives of these radionuclides have an 0. It seems more appropriate now to reotide. J Nucl Med. 2004;45:1168–1171 impact. consider the distribution of energy de- 3. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 Several years ago, O’Donoghue et posited over the pathlength of an emit- DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439–1447. al. determined the optimal tumor cure ted particle on a microscopic scale 4. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor- diameter (lethal dose delivered) as a (even as we have done on a larger scale mediated radiotherapy with 90Y-DOTA-D-Phe1- function of ␤-particle energy (8). They for ␥-radiation) and to relate this dis- Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434. demonstrated that lower-energy emit- tribution to the histopathology for tu- 5. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]- ters are more appropriate for the treat- mors and normal tissues in order to D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the ment of micrometastases, whereas determine the effective radiation-ab- treatment of neuroendocrine tumors: a clinical phase higher-energy ␤-emissions are less ef- sorbed dose on a microscopic anatomic II study. Ann Oncol. 2001;12:941–945. fective in that situation. Given that level. 6. Kwekkeboom DJ, Bakker WH, Kam BL, et al. ␤ Treatment of patients with gastro-entero-pancreatic -labeled carriers (peptides and mono- To understand the relationship be- (GEP) tumours with the novel radiolabelled soma- clonal antibodies) cannot be assumed tween radiation-absorbed dose and ra- tostatin analog [(177)Lu-DOTA(0), Tyr(3) oct- to be uniformly distributed, higher-en- diobiologic response in both tumors reotate. Eur J Nucl Med Mol Imaging. 2003;30:417– 422. ergy radionuclides may be more effec- and normal tissues and organs, we 7. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Tar- tive in larger tumors. Bardies and must determine the microdosimetry; geting metastatic prostate cancer with radiolabeled Chatal (9) have calculated the ab- that is, we need to know the pattern of monoclonal antibody J591 to the extracellular do- sorbed fraction for ␤-emissions of dif- distribution of the radionuclide and ac- main of prostate specific membrane antigen. J Urol. 2003;170:1717–1721. ferent energies as a function of sphere count for the distribution of energy 8. O’Donoghue JA, Bardies M, Wheldon TE. Relation- diameter. deposition on a microscopic and his- ships between tumor size and curability for uni- We must be grateful to Marion de topathologic scale.
Load more

Recommended publications
  • Time, Dose and Fractionation in Radiotherapy
    2/25/2013 The introduction of Fractionation 2-13/13 Radiobiology lecture Time, Dose and Fractionation in Radiotherapy The Four Rs of Radiobiology Repair of Sublethal Damage • Cells exposed to sparse radiation experience • Efficacy of fractionation based on the 4 Rs: sublethal injury that can be repaired – Repair of sublethal damage • Cell killing requires a greater total dose when given –Repopulation in several fractions – Reassortment of cells within the cell cycle • Most tissue repair occurs in about 3 hours and up –Reoxygenation to 24 hours post radiation • Allows for repair of injured normal tissue and gives a potential therapeutic advantage over tumor cells Reoxygenation Redistribution • Oxygen stabilizes free radicals • Position in cell cycle at time of radiation • Hypoxic cells require more radiation to kill determines sensitivity •Hypoxic tumors • S phase is radioresistant – Temporary vessel constriction •G2 phase delay results in increased radiation – Outgrowth of blood supply and capillary collapse resistance • Tumor shrinkage reduces hypoxic areas • Fractionated RT redistributes cells • Reinforces fractionated dosing • Rapidly cycling cells like mucosa, skin are more sensitive • Slower cyclers like connective tissue, brain are spared 1 2/25/2013 Repopulation • Increased regeneration of surviving fraction Basics of Fractionation • Rapidly proliferating tumors regenerate faster • Determines the length and timing of therapy course • Dividing a dose into several fractions spares normal tissues • Accelerated Repopulation – Repair
    [Show full text]
  • Radiobiology Is a Young Science and Is Solely Concerned with the Study Of
    The Rockefeller Foundation and its support of Radiobiology up to the 1970s By Sinclair Wynchank Senior Lecturer University of Cape Town Rondebosch, South Africa [email protected] © 2011 by Sinclair Wynchank Radiation biology, or radiobiology, is a very young science, solely concerned with the study of the interactions between ionizing radiation and living matter. This science slowly became a recognized field of study after the discovery of ionizing radiation (i.e., X rays) in 1895. A broadly varied and evolving terminology has been applied to aspects of radiobiology and therefore, archival searches concerning it are complex. This report is a work in progress, which mainly recounts support given by the Rockefeller Foundation (RF) to radiobiology. The RF was a most important player in the early history of radiobiology and a crucial influence in ensuring that the science steadily matured during its first six decades. Time constraints prevented all relevant items from being accessed, but a clear idea of the RF‟s strong influence on radiobiology‟s early history has resulted. Examples of RF activities to verify this assertion are given below, in by and large chronological order. After a brief analysis of RF aid, there is a short account of why its support so strongly benefitted the young science. To my knowledge there is very little written about the history of radiobiology and nothing about the role that the RF or other philanthropic bodies played in this history. Inevitably, for an extensive time, individual radiobiologists first studied other fields of science before radiobiology. Even in 2011 there are only five universities in the U.S.
    [Show full text]
  • General Guidelines for the Estimation of Committed Effective Dose from Incorporation Monitoring Data
    Forschungszentrum Karlsruhe in der Helmholtz-Gemeinschaftt Wissenschaftliche Berichte FZKA 7243 General Guidelines for the Estimation of Committed Effective Dose from Incorporation Monitoring Data (Project IDEAS – EU Contract No. FIKR-CT2001-00160) H. Doerfel, A. Andrasi, M. Bailey, V. Berkovski, E. Blanchardon, C.-M. Castellani, C. Hurtgen, B. LeGuen, I. Malatova, J. Marsh, J. Stather Hauptabteilung Sicherheit August 2006 Forschungszentrum Karlsruhe in der Helmholtz-Gemeinschaft Wissenschaftliche Berichte FZKA 7243 GENERAL GUIDELINES FOR THE ESTIMATION OF COMMITTED EFFECTIVE DOSE FROM INCORPORATION MONITORING DATA (Project IDEAS – EU Contract No. FIKR-CT2001-00160) H. Doerfel, A. Andrasi 1, M. Bailey 2, V. Berkovski 3, E. Blanchardon 6, C.-M. Castellani 4, C. Hurtgen 5, B. LeGuen 7, I. Malatova 8, J. Marsh 2, J. Stather 2 Hauptabteilung Sicherheit 1 KFKI Atomic Energy Research Institute, Budapest, Hungary 2 Health Protection Agency, Radiation Protection Division, (formerly National Radiological Protection Board), Chilton, Didcot, United Kingdom 3 Radiation Protection Institute, Kiev, Ukraine 4 ENEA Institute for Radiation Protection, Bologna, Italy 5 Belgian Nuclear Research Centre, Mol, Belgium 7 Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses, France 8 Electricité de France (EDF), Saint-Denis, France 9 National Radiation Protection Institute, Praha, Czech Republic Forschungszentrum Karlsruhe GmbH, Karlsruhe 2006 Für diesen Bericht behalten wir uns alle Rechte vor Forschungszentrum Karlsruhe GmbH Postfach 3640, 76021 Karlsruhe Mitglied der Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren (HGF) ISSN 0947-8620 urn:nbn:de:0005-072434 IDEAS General Guidelines – June 2006 Abstract Doses from intakes of radionuclides cannot be measured but must be assessed from monitoring, such as whole body counting or urinary excretion measurements.
    [Show full text]
  • Radiation and Cell Cycle
    High Yield Summary Reviews in Radiation Oncology Radiation and Cancer Biology Gayle E. Woloschak, PhD Tuesday, June 18, 2019 11:00 a.m. – 1:00 p.m. Eastern Daylight Time June 25, 2019 Gayle E. Woloschak PhD Professor of Radiation Oncology, Radiology, and Cell & Molecular Biology Associate Dean for Graduate Student and Postdoctoral Affairs Northwestern University Feinberg School of Medicine June 25, 2019 Definitions • Bq-2.7x10-11 Ci—equal to one disintegration per sec • Ci—3.7x1010 disintegrations per sec • Gy—absorbed radiation dose, the quantity which deposits 1 Joule of energy per kg—1Gy=100rad • Sievert—dose equivalence—multiply absorbed dose in Gy by the Quality Factor (Q)— 1Sv=100rem • LET—measure of the rate of energy transfer from an ionizing radiation to the target material—keV of energy lost/micron track length Unit Conversion Factors: SI and Conventional Units • 1 Bq = 2.7 × 10–11 Ci = 27 pCi • 1 Ci = 3.7 × 1010 Bq = 37 GBq • 1 Sv = 100 rem • 1 rem = 0.01 Sv • 1 Gy = 100 rad • 1 rad = 0.01 Gy • 1 Sv Bq–1 = 3.7 × 106 rem μCi–1 • 1 rem μCi–1 = 2.7 × 10–7 Sv Bq–1 • 1 Gy Bq–1 = 3,7 × 106 rad μCi–1 • 1 rad μCi–1 = 2,7 × 10–7 Gy Bq–1 Biomolecular Action of Ionizing Radiation; Editor:Shirley Lehnert, 2007 Units Used in Radiation Protection • Equivalent dose—average dose x radiation weighting factor—Sv • Effective dose—sum of equivalent doses to organs and tissues exposed, each multiplied by the appropriate tissue weighting factor—Sv • Committed equivalent dose—equivalent dose integrated over 50 years (relevant to incroporated radionuclides)—Sv
    [Show full text]
  • Proton Radiobiology
    Cancers 2015, 7, 353-381; doi:10.3390/cancers7010353 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Proton Radiobiology Francesco Tommasino 1 and Marco Durante 1,2,* 1 GSI Helmholtzzentrum für Schwerionenforschung, Department of Biophysics, Darmstadt 64291, Germany; E-Mail: [email protected] 2 Technische Universität Darmstadt, Institut für Festkörperphysik, Darmstadt 64291, Germany * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-6159-71-2009. Academic Editor: Xiaodong Zhang Received: 3 December 2014 / Accepted: 9 February 2015 / Published: 12 February 2015 Abstract: In addition to the physical advantages (Bragg peak), the use of charged particles in cancer therapy can be associated with distinct biological effects compared to X-rays. While heavy ions (densely ionizing radiation) are known to have an energy- and charge-dependent increased Relative Biological Effectiveness (RBE), protons should not be very different from sparsely ionizing photons. A slightly increased biological effectiveness is taken into account in proton treatment planning by assuming a fixed RBE of 1.1 for the whole radiation field. However, data emerging from recent studies suggest that, for several end points of clinical relevance, the biological response is differentially modulated by protons compared to photons. In parallel, research in the field of medical physics highlighted how variations in RBE that are currently neglected might actually result in deposition of significant doses in healthy organs. This seems to be relevant in particular for normal tissues in the entrance region and for organs at risk close behind the tumor. All these aspects will be considered and discussed in this review, highlighting how a re-discussion of the role of a variable RBE in proton therapy might be well-timed.
    [Show full text]
  • Radiobiology
    The Management of Gynecologic Cancers: Radiobiology Brian Marples PhD Beaumont Health Systems Overview of presentation • Assessment of normal tissue response • Radiobiology modeling • Role of HPV in tumor response • Hypoxic and tumor response Radiobiology and normal tissue response and tolerance • The Emami paper (IJROBP 21: 109–122 1991) – 1/3, 2/3, whole organs - some clinical, some laboratory data – Consensus of clinical experience and opinions – Concerns with delivered dose and measurements of dose – Out of date: Move from 2D to 3D treatment planning, higher energy beams, better penetration, improved ability to measure dose, increased use combined therapy • Quantitative – QUANTEC, CTCAE v4.0, LENT-SOMA, IIEF – Quantitative Analysis of Normal Tissue Effects in the Clinic – Updated guidelines published in Red Journal • IJROBP vol 76, No., 3 2010 (suppl.) – 16 organ-specific papers – Radiation dose-volume effects of the urinary bladder • Viswanathan et al. IJROBP 76: 3: S116–S122, 2010 • Cervix BRT: size of 60-Gy volume and dose rate have impact on late rectal complication BED = Biologically Effective Dose • BED commonly used for isoeffective dose calculations • BED is a measure of the true biological dose delivered by a particular combination of dose per fraction and total dose to a particular tissue characterized by a specific α/β ratio • BED is not Biologically Equivalent Dose • Biologically equivalent doses are calculated in 2-Gy equivalents using the EQD2 equation • Cumulative: brachytherapy dose added to the dose from external beam therapy Bentzen et al., Radiother Oncol 105: 266–268, 2012 Dale, Br J Radiol 58: 515–528, 1985 Biologically Effective Dose (BED) • BED compare effects fractionation schedules – need to know α/β ratio of the tissues concerned BED = total dose .
    [Show full text]
  • Risk of Acute Radiation Syndromes Due to Solar Particle Events
    Evidence Report: Risk of Acute Radiation Syndromes due to Solar Particle Events Human Research Program Space Radiation Program Element Approved for Public Release: April 6, 2016 National Aeronautics and Space Administration Lyndon B. Johnson Space Center Houston, Texas CURRENT CONTRIBUTING AUTHORS: Lisa Carnell, PhD NASA Langley Research Center, Hampton, VA Steve Blattnig, PhD NASA Langley Research Center, Hampton, VA Shaowen Hu, PhD Wyle Science Technology & Engineering, Houston, TX Janice Huff, PhD Universities Space Research Association, Houston, TX Myung-Hee Kim, PhD Wyle Science Technology & Engineering, Houston, TX Ryan Norman, PhD NASA Langley Research Center, Hampton, VA Zarana Patel, PhD Wyle Science Technology & Engineering, Houston, TX Lisa Simonsen, PhD NASA Langley Research Center, Hampton, VA Honglu Wu, PhD NASA Johnson Space Center, Houston, TX PREVIOUS CONTRIBUTING AUTHORS: Honglu Wu NASA Johnson Space Center Janice L. Huff Universities Space Research Association Rachel Casey Universities Space Research Association Myung-Hee Kim Universities Space Research Association Francis A. Cucinotta NASA Johnson Space Center Reference for original report: Human Health and Performance Risks of Space Exploration Missions, (Jancy C. McPhee and John B. Charles, editors), NASA SP-2009- 3405, 2009. 1 Table of Contents I. PRD RISK TITLE: RISK OF ACUTE RADIATION SYNDROMES DUE TO SOLAR PARTICLE EVENTS ........................................................................................... 4 II. EXECUTIVE SUMMARY ................................................................................................
    [Show full text]
  • Radiobiology of Tissue Reactions
    Radiobiology of tissue reactions W. Do¨ rr Department of Radiation Oncology and Christian Doppler Laboratory for Medical Radiation Research for Radiooncology, Comprehensive Cancer Centre, Medical University Vienna/ Vienna General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria; e-mail: [email protected] Abstract–Tissue effects of radiation exposure are observed in virtually all normal tissues, with interactions when several organs are involved. Early reactions occur in turnover tissues, where proliferative impairment results in hypoplasia; late reactions, based on combined parenchy- mal, vascular, and connective tissue changes, result in loss of function within the exposed volume; consequential late effects develop through interactions between early and late effects in the same organ; and very late effects are dominated by vascular sequelae. Invariably, involvement of the immune system is observed. Importantly, latent times of late effects are inversely dependent on the biologically equieffective dose. Each tissue component and – importantly – each individual symptom/endpoint displays a specific dose–effect relationship. Equieffective doses are modulated by exposure conditions: in particular, dose-rate reduction – down to chronic levels – and dose fractionation impact on late responding tissues, while overall exposure time predominantly affects early (and consequential late) reactions. Consequences of partial organ exposure are related to tissue architecture. In ‘tubular’ organs (gastrointestinal tract, but also vasculature), punctual exposure affects function in downstream compartments. In ‘parallel’ organs, such as liver or lungs, only exposure of a significant (organ-dependent) fraction of the total volume results in clinical consequences. Forthcoming studies must address biomarkers of the individual risk for tissue reactions, and strategies to prevent/mitigate tissue effects after exposure.
    [Show full text]
  • Preliminary Program
    PRELIMINARY PROGRAM 55th Annual Meeting of the Health Physics Society 22nd Biennial Campus Radiation Safety Officers Meeting (American Conference of Radiological Safety) 27 June - 1 July 2010 Salt Palace Convention Center Salt Lake City, Utah Key Dates Current Events/Works-In-Progress Deadline . .28 May Social/Technical Preregistration Deadline . .31 May HPS Annual Meeting Preregistration Deadline . 31 May PEP Preregistration Deadline . .31 May Hotel Registration Deadline . 5 June AAHP Courses . 26 June Professional Enrichment Program . 27 June - 1 July HPS 55th Annual Meeting . 27 June - 1 July American Board of Health Physics Written Exam . 28 June Registration Hours and Location Registration at the Salt Palace Convention Center - Foyer of Exhibit Hall A Saturday, 26 June . 2:00 - 5:00 pm Sunday, 27 June . 10:00 am - 5:00 pm Monday, 28 June . 8:00 am - 4:00 pm Tuesday, 29 June . 8:00 am - 4:00 pm Wednesday, 30 June . 8:00 am - 4:00 pm Thursday, 1 July . 8:00 - 11:00 am Saturday Saturday AAHP Courses will take place in the Hilton Hotel Sunday - Thursday All PEPs, CELs and Sessions will be at the Salt Palace Convention Center HPS Secretariat 1313 Dolley Madison Blvd. Suite 402 McLean, VA22101 (703) 790-1745; FAX: (703) 790-2672 Email: [email protected]; Website: www.hps.org 1 Table of Contents Important Events . 6 General Information . 7 Hotel Reservation Information . 7 Tours and Events Listing . 9 Scientific Program . 12 Placement Information . 32 AAHP Courses . 33 Professional Enrichment Program . 34 Continuing Education Lecture Abstracts . 46 Annual Meeting Registration Form . 48-49 CURRENT EVENTS/WORKS-IN-PROGRESS The submission form for the Current Events/Works-in-Progress poster session is on the Health Physics Society Website at www .hps .org under the Salt Lake City Annual Meeting section .
    [Show full text]
  • Radiobiology of Radionuclide Therapy Prof Sarah Baatout [email protected]
    Radiobiology of radionuclide therapy Prof Sarah Baatout [email protected] Head of the Radiobiology Unit, SCK•CEN Faculty of Biosciences Engineering, Universiteit Gent, Belgium Faculté des Sciences, Université de Namur, Belgium International Course on THERANOSTICS AND RADIOTHERAPY, A Joint Initiative of IAEA-BELNUC-Institut Bordet 2-6/10/2017 © SCK•CEN Academy Cancer definition . Many definitions . Definition (used by ASC) : . Cancer is a large group of diseases characterized by the uncontrolled growth and spread of abnormal cells. If the spread is not controlled, it can result in death. Treatment requires a multidisciplinary approach © SCK•CEN Academy What is/causes cancer? . It is thought that several mutations need to occur to give rise to cancer. Mutations of normal genes : . oncogenes linked to accelerated cell proliferation . tumour suppressor genes linked to decreased cell death. over 100s forms of cancer © SCK•CEN Academy What causes cancer? . Cells that are old or not functioning properly normally self destruct and are replaced by new cells. However, cancerous cells do not self destruct and continue to divide rapidly producing millions of new cancerous cells. At least 5 mutations Normal Cell Cancer Cell Obeys strict rules Disobeys rules Divides only when told to Divides at will Dies rather than misbehaving Bad behavior doesn’t kill Stays close to home Wanders through body Careful with chromosomes Careless with chromosomes © SCK•CEN Academy Cancer cure = minimum killing of 99,9% cells 5 © SCK•CEN Academy Situation in Belgium In 2013, 65,847 new cancer diagnoses in Belgium 34,542 in men (53%) 30,945 in women (47%) Before 75th anniversary 59% 69% are still alive 5 years after diagnosis 3% of the Belgian population is living with cancer or has been diagnosed with cancer in the last 10 years 13% of patients with cancer have multiple tumours Estimation for 2025 12,000 more new diagnoses than in 2013.
    [Show full text]
  • THE PHYSICAL and BIOLOGICAL BASIS of RADIATION ONCOLOGY Ever Since the Discovery of X-Ray by Rontgen, a German Physicist in 1985
    THE PHYSICAL AND BIOLOGICAL BASIS OF RADIATION ONCOLOGY Ever since the discovery of x‐ray by Rontgen, a German physicist in 1985, x‐ray has been used in various types of medical procedures. The very first medical use of x‐rays was reported in January of 1896 which indicated that the x‐rays were used to locate a piece of a knife in the backbone of a drunken sailor who was paralyzed until the fragment was removed following its localization. At that time this new technology very rapidly spread through Europe and the United States and the field of diagnostic radiology was born. Not too long after that the radiation was used to treat shallow tumors of the skin by doctors. RADIOBIOLOGY Radiobiology is the study of the action of ionizing radiation on living things. This certainly involves a fair amount of radiation physics and a good understanding of various types of ionizing radiation as well as a description of the physics and chemistry of the processes by which radiation is absorbed. X‐ray was discovered in December 1895 by a German Physicist “Wilhelm Conrad Rontgen”. First medical use of X‐ray is reported as early as January 1896. After this time, the field of Radiology was born. Reports indicate the first therapeutic use of X‐ray was in 1897 to treat skin melanoma. Radioactivity was discovered by “Antonio Henri Becquerel” in 1898. Radium was isolated by “Pierre & Marie Curie” also in 1898. Rad_Bio; Physics and Chemistry of X‐ray absorption pg. 1 of 20 First recorded radiobiology experiment was performed by Becquerel, when he inadvertently left a Radium container in his pocket, resulting in skin erythema that came about 2 weeks later.
    [Show full text]
  • The Radiobiological Four "R"S of Hypofractionation
    The Radiobiological Four "R"s of Hypofractionation Brian Marples PhD Beaumont Health Systems Overview of the presentation • Definition of hypofractionation • Radiobiology – 4 R’s – Standard fraction dosing • Linear quadratic (LQ) model – is it valid? – Radiosensitivity – 5th R of radiobiology • 4 R’s radiobiology of SBRT/SRS – Cell cycle, vascular effects, hypoxia, DNA repair • Conclusions Hypofractionation, SRS, SBRT [SABR] • Conventional fractionation (1.8-2 Gy) • Hypofractionation – doses of 2.5 Gy and above • Stereotactic radiosurgery (SRS) – entire dose is given in a single fraction – extreme example of SBRT– ablative doses of RT • Stereotactic body radiation therapy (SBRT) – a.k.a. stereotactic ablative radiation therapy (SABR) – defined as treatment of tumors with 1 to 5/8 dose fractions – SBRT paradigm shift from the practice of radiation therapy – uncontested that conventional RT better for normal tissues 4 R’s of radiobiology • Repopulation, Redistribution, Repair & Reoxygenation • Enabled development of safe and effective dose- fractionation regimens – along with a rudimentary appreciation of why treatment may succeed or fail (CHART v EORTC22851) • Understanding the 4R’s allows the concomitant use of drugs: – Repopulation, redistribution, repair and re-oxygenation – EGFR blockade by cetuximab in Head and Neck • Bonner et al. N Engl J Med 2006;354(6): – Use of DNA repair inhibitor – Inhibitors of neo-vascularization in glioma 4(5) R’s of conventional fractionated RT “factors work in opposite directions” • Redistribution (Reassortment): Sensitize tumors – cell-cycle progression into RT-sensitive phases • Repopulation and Repair – tumors: decreases radiation sensitivity – early-reacting normal tissues: increase in radiation tolerance with increasing overall treatment time • Reoxygenation: Sensitize tumors – oxygenation of surviving hypoxic cells • Radiosensitivity (5th R) – intrinsic sensitivity of tumor: modeled by LQ Steel, McMillan, Peacock.
    [Show full text]